Cosmos Health Restarts Share Repurchases to Tackle Undervalued Stock

Cosmos Health Restarts Share Repurchases to Tackle Undervalued Stock

2026-11-19 companies

Chicago, Thursday, 19 November 2026.
Cosmos Health resumed its buyback program with $3.85 million remaining, reinforced by company leaders committing to a 12-month share lock-up to signal firm alignment with investors.

Resumption of Share Repurchases Under Existing Program

On November 18, 2026, Cosmos Health Inc. (NASDAQ: COSM) announced the resumption of open-market share repurchases under its $5.0 million share repurchase program [1][4][5]. As of that date, approximately $3.85 million remained available under the authorization, which was initially approved by the Board of Directors on June 26, 2026 [1][4]. The program permits repurchases from time to time under Rule 10b-18 of the Securities Exchange Act of 1934, subject to prevailing market conditions [1][4]. By November 18, 2026, Cosmos Health had repurchased a total of 255,600 shares (5,112,000 pre-split) for approximately $1.15 million, leaving the remaining $3.85 million available for future buybacks [1][4][5].

Insider Commitments Reinforce Long-Term Confidence

In a complementary move, executive officers and members of the Board of Directors of Cosmos Health entered into a 12-month lock-up commitment on all shares of common stock they currently hold, effective November 18, 2026 [1][4]. This voluntary agreement aligns insider interests with those of public shareholders and signals management’s confidence in the company’s long-term prospects. Speaking on the dual initiatives, CEO Greg Siokas stated, ‘We are putting both the Company’s capital and our own shares behind our conviction in Cosmos Health. Resuming our buyback and committing our officers and Board to a 12-month lock-up send a clear message: our leadership is invested for the long term’ [1][4].

Financial Momentum and Strategic Growth Underpin Shareholder Actions

Cosmos Health’s decision to restart its buyback program follows a period of significant financial and operational progress. The company reported record nine-month revenue of $53.59 million for the period ending September 30, 2026, representing a 17.6% increase year-over-year from $45.57 million [2][3][5]. Despite the top-line growth, the company reported a nine-month net loss of $14.15 million, up from $9.00 million in the prior period [2][3][5]. However, key balance sheet improvements were noted, including a 33.8% reduction in total debt to $12.83 million and a 21.2% increase in stockholders’ equity to $22.33 million as of September 30, 2026 [2][3][5]. Additionally, the company fully settled its $8.0 million ATW convertible note ahead of its August 2027 maturity, further strengthening liquidity and reducing financial leverage [2][3][5].

Operational Highlights Fuel Growth Outlook

Beyond financial restructuring, Cosmos Health has made notable strides in its operational segments. The U.S. direct-to-consumer business achieved over 12,500 active subscriptions by October 31, 2026, with a monthly subscription value of $1.83 million, translating to an annualized run rate of approximately $22 million [2][3][5]. The company also reported a sequential rebound in gross margin, which increased by 465 basis points to 12.6% in Q3 2026 from 7.96% in Q2 2026 [2][3][5]. Adjusted EBITDA loss improved by approximately 18% sequentially to $0.93 million, indicating operational efficiency gains [2][3][5]. Cosmos Health’s contract manufacturing pipeline has expanded to over 32.7 million units, and the company has entered new markets including Saudi Arabia and Oceania, alongside automation upgrades at CosmoFarm [2][3][5].

Strategic Vision and Future Initiatives

Looking ahead, Cosmos Health has outlined plans to explore tokenization of its CCX0722 hydrogel intellectual property in a non-dilutive financing structure targeting the $562 billion weight-management market [3][5]. This initiative, while still in exploratory stages, underscores the company’s ambition to leverage innovative capital strategies to fund growth without equity dilution [3][5]. Management emphasized that the combination of strengthened financials, record revenue performance, and expanding subscription and manufacturing platforms positions Cosmos Health well for continued growth in 2027 and beyond [1][2][3][4][5].

Sources


share repurchase insider lock-up